论文部分内容阅读
目的:探讨国家基本药物生脉注射液不良反应(ADR)发生的情况及相关因素,寻找ADR发生的原因及预防措施,为临床合理用药提供参考。方法:对公开出版的1989～2009年文献报道的60例生脉注射液ADR报告从年龄分布、ADR累及器官/系统分布及临床表现进行分析。结果:生脉注射液ADR以过敏反应为多见(包括皮疹、荨麻疹、结膜水肿、发热、寒战、过敏性休克),共34例,占56.67%;其次是胃肠系统,共7例,占11.67%;心血管系统7例,占11.67%;其他散见于心血管系统反应、视觉损害、局部疼痛等。结论:临床医务人员应了解生脉注射液ADR的特点及发病机制,掌握其应用的时机,以及防范的措施,规范合理用药,避免或减少ADR的发生。
Objective: To investigate the occurrence and related factors of adverse reactions of Shengmai injection (ADR) of national essential drugs, to find out the causes and preventive measures of ADR, and to provide a reference for clinical rational drug use. Methods: 60 cases of Shengmai injection ADR reported in the published literature from 1989 to 2009 were analyzed from the age distribution, ADR involved organ / system distribution and clinical manifestations. Results: There were 34 cases (56.67%) of allergic reaction in Shengmai Injection ADR, including gastrointestinal system, 7 cases of allergic shock, rash, urticaria, conjunctival edema, fever, chills and anaphylactic shock. Accounting for 11.67%; cardiovascular system in 7 cases, accounting for 11.67%; other scattered in the cardiovascular system reaction, visual impairment, local pain and so on. Conclusion: Clinical medical staff should understand the characteristics and pathogenesis of ADR of Shengmai injection, grasp the timing of its application and preventive measures, regulate the rational use of drugs and avoid or reduce the occurrence of ADR.